Peptide Oncology Safety Tiers
TL;DR
This note defines the oncology-specific safety tier framework for all peptides in the Vitals program. It is the primary safety reference for cancer-relevant peptide decisions. No peptide in this program has Phase I human evidence for anticancer efficacy.
The 3-Tier Framework
Tier 1 — Evidence of Safety in Cancer Context
Definition: Peptides with clinical evidence of safety specifically in oncology settings.
Current status: ⚠️ No peptide currently holds Tier 1. No peptide in this program has completed Phase I testing for anticancer efficacy.
Tier 2 — Caution Required
Definition: Theoretical concern or limited preclinical data. These peptides are not contraindicated outright but require clinical consultation before use in cancer survivors or active cancer patients.
Peptides in this tier:
| Peptide | Mechanism | Cancer Relevance | Key Uncertainty |
|---|---|---|---|
| Epithalon | Telomerase activation | H4, H11 | Risk depends on p53 status; unresolved in p53-mutant cells |
| Retatrutide | Autophagy modulation | H1 | Direction entirely context-dependent |
| BPC-157 | Tissue repair; anti-inflammatory | H5, H8 | Angiogenesis duality — pro-angiogenic in wound healing, anti-angiogenic in some tumor models |
| GHK-Cu | DNA repair support; anti-inflammatory; ECM remodeling | H7, H8, H12 | Context-dependent; direction of ECM effect in tumors unclear |
| PCC1 (procyanidin C1) | Senolytic | H10, H14 | Most mechanistically promising peptide concept in the program — no human senolytic efficacy data |
| MOTS-c | mTOR antagonism; metabolic reprogramming | H1 | Theoretical; AMPK activation direction context-dependent |
Tier 2 guidance for cancer survivors (NED):
- Exercise caution. No long-term safety data exists for any peptide in this population.
- Growth factor peptides (Tier 3) should be held.
- Telomerase activators require p53 status disclosure.
- Autophagy modulators are context-dependent.
Tier 3 — Contraindicated in Active Cancer or Dysplasia
Definition: These peptides carry a theoretical or demonstrated mitogenic risk and should not be used by individuals with active cancer, confirmed dysplasia, or premalignant conditions.
Peptides in this tier:
| Peptide | Mechanism | Risk |
|---|---|---|
| GHRP-2 | GHSR agonist — GH/IGF-1 axis activation | IGF-1 is a mitogen driving proliferation in many cancers |
| GHRP-6 | GHSR agonist — GH/IGF-1 axis activation | Same as GHRP-2 |
| CJC-1295 | GHRH analog — GH pulse amplification | Upregulates IGF-1; theoretical risk of promoting EMT (H6) and proliferation (H1) |
⚠️ IGF-1 is a mitogen. Peptides activating the GH/IGF-1 axis are contraindicated in active cancer and require oncologist approval for use in cancer survivors with NED.
The Translation Gap — Why Tier 2 Is Not Tier 1
| Evidence Level | Reality |
|---|---|
| In vitro IC50 | Typically achieved at concentrations 10–100× higher than achievable in human plasma at safe dosing |
| Mouse xenograft models | Do not reliably predict human solid tumor response |
| Human Phase I efficacy | No peptide in this program has completed Phase I for anticancer efficacy |
Source: PMC12838956 — “robustly validated in preclinical studies, clinical translation remains unproven.”
Immunotherapy Combination Hypotheses
| Peptide | Immunotherapy | Mechanistic Rationale | Evidence Level |
|---|---|---|---|
| GHK-Cu | PD-1/CTLA-4 | May reduce TAM/MDSC infiltration → TME remodeling | Theoretical |
| BPC-157 | PD-1/CTLA-4 | Anti-inflammatory may reduce checkpoint upregulation | Theoretical |
| PCC1 senolytic | PD-1/CTLA-4 | Removing SASP cells reduces immunosuppressive niche | Theoretical |
| GHRP-2/GHRP-6/CJC-1295 | PD-1/CTLA-4 | May antagonize — IGF-1 promotes T-cell exhaustion | Theoretical |
No human combination data exists for any peptide in this program.
Vitals Algorithm Safety Gates
| Condition | Action | Peptides Affected |
|---|---|---|
| Active cancer | Block all peptide recommendations; flag for clinical consultation required | ALL — no Tier 1 evidence |
| Cancer survivor NED | Block GH/IGF-1 axis peptides (Tier 3); require oncologist approval for Tier 2 | GHRP-2, GHRP-6, CJC-1295, Epithalon |
| Known dysplasia | Block telomerase activators; require clinical consultation | Epithalon |
Biomarker Reality Check
| Tool | Cancer Relevance | Limitation |
|---|---|---|
| PSA | Prostate screening/monitoring | Elevated in BPH, prostatitis |
| CA-125 | Ovarian monitoring (not screening) | Elevated in endometriosis, PID |
| CEA | Colorectal monitoring | Elevated in smoking, IBD |
| ctDNA (Guardant360, FoundationOne) | Molecular profiling, MRD | Not validated for screening |
| Consumer wearables (Apple Watch, Whoop, Oura) | Not validated for cancer detection or monitoring | RHR, HRV, sleep signals are non-specific |
Consumer wearables cannot distinguish cancer from infection, cardiovascular disease, dehydration, or dozens of other conditions.
Key Takeaways
- No peptide is Tier 1 — no peptide in this program has oncology safety evidence in humans.
- Tier 3 peptides are contraindicated in active cancer — GH/IGF-1 axis peptides are mitogenic.
- Tier 2 peptides require clinical consultation before use in cancer survivors.
- PCC1 senolytic is the most mechanistically interesting concept in the program (H10/H14) but has no human efficacy data.
- No peptide should be used by cancer patients or survivors without consulting an oncologist.
Related Notes
- Hallmarks of Cancer — The 14 hallmarks framework
- Tumor Microenvironment — TME as therapeutic barrier
- Peptides MOC — Peptide hub notes (PCC1, Epithalon, BPC-157, GHK-Cu, etc.)
- Epithalon — Telomerase activator (Tier 2)
- PCC1 — Senolytic polyphenol (Tier 2)
- BPC-157 — Tissue repair pentadecapeptide (Tier 2)
- GHK-Cu — Copper tripeptide (Tier 2)
Source: Hallmarks of Cancer v2 canonical monograph (batch 20) · Safety tier framework